Clinically Relevant Biomarker Discovery in High-Risk Recurrent Neuroblastoma

Area of Science:

• Pediatric Oncology
• Cancer Genomics
• Biomarker Discovery

Background:

• Neuroblastoma recurrence is aggressive and treatment-refractory.
• Early identification of non-responders is crucial for high-risk neuroblastoma patients.
• Novel biomarkers are needed to predict treatment efficacy and recurrence risk.

Purpose of the Study:

• To identify molecular biomarkers for predicting treatment response and recurrence in high-risk neuroblastoma.
• To analyze expression profiles of messenger RNAs (mRNAs) and long non-coding RNAs (lncRNAs) in neuroblastoma cell lines before and after therapy.
• To correlate gene expression with patient outcomes.

Main Methods:

• Next-generation sequencing to profile mRNA and lncRNA expression in neuroblastoma cell lines.
• Partial least squares-discriminant analysis (PLS-DA) with LASSO and cross-validation to identify differentially expressed genes.
• Analysis of a neuroblastoma patient cohort to validate biomarker candidates.
• Gene set enrichment analysis (GSEA) to determine functional pathways.

Main Results:

• Identified 55 mRNAs and 17 lncRNAs with altered expression between primary and recurrent neuroblastoma cell lines.
• 20 protein-coding genes and 6 lncRNAs showed differential expression correlating with patient outcome.
• Identified miRNA-mRNA interactions involving specific miRNAs and their target genes.

Conclusions:

• The identified genes and lncRNAs may serve as predictive biomarkers for neuroblastoma treatment response and recurrence.
• These findings provide a basis for further investigation into therapeutic strategies targeting identified molecular pathways.
• The study highlights the utility of clinically relevant models for biomarker discovery in pediatric cancers.